Close

Nephros Licenses HydraGuard Military Filter to CamelBak®

RIVER EDGE, NJ, May 6, 2015 /Businesswire/ — Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today that the Company has exclusively licensed its HydraGuard military filter to CamelBak®

Under the terms of the agreement, CamelBak shall have the exclusive right to market and sell the HydraGuard military filter under the CamelBak brand name. Financial terms were not disclosed.

HydraGuard Products

The HydraGuard Inline Purifier is an IWP (Individual Water Purifier) developed for in-line use with personal hydration systems and gravity feed systems. CPC, MOLLE/ILBE/USMC Compatible – Can be used with any hydration reservoir and gravity feed.

The HydraGuard Universal Purifier is an IWP developed for stand-alone point-of-use with most water bottles, canteens, or directly as a straw. Quick adapter system – easily connects to standard issue military canteens and most water bottles.

“CamelBak is the global leader in personal hydration gear, and Nephros is proud to have the HydraGuard join their prestigious product line,” said Daron Evans, CEO of Nephros. “CamelBak’s significant capabilities and expertise in the military and outdoors markets will help Nephros maximize HydraGuard’s commercial potential while allowing us to focus on our core products.”

“We are excited to include the HydraGuard within the CamelBak product portfolio,” said Sally McCoy, CEO of CamelBak. “It provides a one-step water purification solution which has been validated to meet the Army’s NSF P248 specifications.”

About CamelBak®
Founded in 1989, CamelBak invented the hands-free hydration category and is the global leader in personal hydration gear. CamelBak is achieving its mission to continually reinvent and forever change the way people hydrate and perform by offering a mix of products that include everything from technical hydration packs to reusable bottles and individual UV purification systems.

With headquarters in Petaluma, Calif., a wholly-owned and operated reservoir manufacturing facility in Mexico and a distribution facility in San Diego, Calif., CamelBak designs, tests and engineers its products to perform and last a lifetime. CamelBak is owned by Compass Diversified Holdings (NYSE: CODI), and offers products in more than 50 countries. For more information, please visit www.camelbak.com.

About Nephros, Inc.
Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. Its filters, which it calls ultrafilters, are primarily used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and/or blood.

Nephros was founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center/New York-Presbyterian Hospital to develop and commercialize an alternative method to hemodialysis (HD). The company has extended its filtration technologies to meet the demand for liquid purification in other areas, in particular water purification.

For more information about Nephros and its products, please visit the company’s website at www.nephros.com.
Forward-Looking Statements

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the commercialization of Nephros’ HydraGuard products and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros Inc.’s reports filed with the U.S. Securities and Exchange Commission, including with respect to Nephros, its Annual Report on Form 10-K for the year ended December 31, 2014. Nephros, Inc. and CamelBak, together or separately, do not undertake any responsibility to update the forward-looking statements in this release.

Contact:
Investor:
PCG Advisory Group
Kirin M. Smith, Chief Operating Officer
Direct: 646-863-6519
www.pcgadvisory.com

Click Here to view External Links